ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Kaken Pharmaceutical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -0.13% and Operating profit at -172.57% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
- NET PROFIT(9M) At JPY 2,604.52 MM has Grown at -81.09%
- NET SALES(HY) At JPY 37,515 MM has Grown at -12.07%
- RAW MATERIAL COST(Y) Grown by 8.25% (YoY)
3
With ROE of -1.26%, it has a risky valuation with a 1.30 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 0.92%, its profits have fallen by -108.9%
- At the current price, the company has a high dividend yield of 0
4
Underperformed the market in the last 1 year
- The stock has generated a return of 0.92% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 85.83%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Kaken Pharmaceutical Co., Ltd. for you?
Low Risk, High Return
Absolute
Risk Adjusted
Volatility
Kaken Pharmaceutical Co., Ltd.
0.76%
1206.21
17.93%
Japan Nikkei 225
75.22%
3.09
27.80%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-0.13%
EBIT Growth (5y)
-172.57%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.54
Tax Ratio
28.25%
Dividend Payout Ratio
52.00%
Pledged Shares
0
Institutional Holding
0.10%
ROCE (avg)
20.37%
ROE (avg)
8.17%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.30
EV to EBIT
-38.54
EV to EBITDA
-165.09
EV to Capital Employed
1.42
EV to Sales
1.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.69%
ROE (Latest)
-1.26%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
DIVIDEND PAYOUT RATIO(Y)
Highest at 482.24%
DIVIDEND PER SHARE(HY)
Highest at JPY 3.5
PRE-TAX PROFIT(Q)
Highest at JPY 1,074 MM
NET PROFIT(Q)
Highest at JPY 1,491 MM
EPS(Q)
Highest at JPY 19.7
-27What is not working for the Company
NET PROFIT(9M)
At JPY 2,604.52 MM has Grown at -81.09%
NET SALES(HY)
At JPY 37,515 MM has Grown at -12.07%
RAW MATERIAL COST(Y)
Grown by 8.25% (YoY
CASH AND EQV(HY)
Lowest at JPY 96,543 MM
DEBT-EQUITY RATIO
(HY)
Highest at -31.68 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.93 times
INTEREST(Q)
Highest at JPY 13 MM
Here's what is working for Kaken Pharmaceutical Co., Ltd.
Pre-Tax Profit
At JPY 1,074 MM has Grown at 123.47%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (JPY MM)
Net Profit
At JPY 1,491 MM has Grown at 146.3%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Pre-Tax Profit
Highest at JPY 1,074 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 1,491 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY 19.7
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Dividend per share
Highest at JPY 3.5
in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (JPY)
Dividend Payout Ratio
Highest at 482.24%
in the last five yearsMOJO Watch
Company is distributing higher proportion of profits generated as dividend
DPR (%)
Depreciation
Highest at JPY 1,018 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Here's what is not working for Kaken Pharmaceutical Co., Ltd.
Interest
At JPY 13 MM has Grown at 18.18%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Net Sales
At JPY 37,515 MM has Grown at -12.07%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (JPY MM)
Interest
Highest at JPY 13 MM
in the last five periods and Increased by 18.18% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Cash and Eqv
Lowest at JPY 96,543 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -31.68 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 1.93 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Raw Material Cost
Grown by 8.25% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
